CN108578606B - Traditional Chinese medicine preparation for treating rheumatoid arthritis - Google Patents

Traditional Chinese medicine preparation for treating rheumatoid arthritis Download PDF

Info

Publication number
CN108578606B
CN108578606B CN201810865992.2A CN201810865992A CN108578606B CN 108578606 B CN108578606 B CN 108578606B CN 201810865992 A CN201810865992 A CN 201810865992A CN 108578606 B CN108578606 B CN 108578606B
Authority
CN
China
Prior art keywords
parts
traditional chinese
group
chinese medicine
rheumatoid arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810865992.2A
Other languages
Chinese (zh)
Other versions
CN108578606A (en
Inventor
王青山
白长川
张琳
侯丽艳
肖楠
何世勇
黄瑞雪
薛崇祥
乔艳皊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian Medical University
Original Assignee
Dalian Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian Medical University filed Critical Dalian Medical University
Priority to CN201810865992.2A priority Critical patent/CN108578606B/en
Publication of CN108578606A publication Critical patent/CN108578606A/en
Application granted granted Critical
Publication of CN108578606B publication Critical patent/CN108578606B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994—Coix (Job's tears)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/237—Notopterygium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/238—Saposhnikovia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A61K36/515—Gentiana
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/714—Aconitum (monkshood)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a traditional Chinese medicine preparation for treating rheumatoid arthritis, which is an oral traditional Chinese medicine water extract, and the traditional Chinese medicines comprise the following components in percentage by mass: 35 parts of astragalus membranaceus, 15 parts of cassia twig, 25 parts of fried white peony root, 10 parts of fried monkshood, 15 parts of angelica, 25 parts of coix seed, 15 parts of divaricate saposhnikovia root, 15 parts of large-leaved gentian, 10 parts of notopterygium root, 10 parts of ligusticum wallichii, 15 parts of rhizoma atractylodis and 15 parts of liquorice. The side effect of the traditional Chinese medicine composition for treating rheumatoid arthritis is small, and the results of detection on the joint swelling degree of a treated mouse and the contents of RF, TNF alpha, IL-6 and IL-10 in serum show that the traditional Chinese medicine composition has better curative effect on rheumatoid arthritis than the prior art.

Description

Traditional Chinese medicine preparation for treating rheumatoid arthritis
Technical Field
The invention relates to a traditional Chinese medicine preparation, in particular to a traditional Chinese medicine preparation for treating rheumatoid arthritis with small side effect and good curative effect.
Background
Rheumatoid Arthritis (RA) is a systemic immune arthritis and one of the chronic diseases that seriously threaten health. It is mainly characterized by chronic, symmetrical, progressive and invasive properties, and is particularly characterized by arthrocele deformation and bone destruction, even disability, caused by arthromeningitis. The etiology and pathogenesis of RA has not been elucidated, and inflammatory changes are typical pathological changes thereof, and the immune system and synovial tissue cells and cytokines secreted therefrom exacerbate the progression of the disease. In recent years, researchers at home and abroad propose, according to evidence-based medical evidence, that the treatment goal of RA is to enable patients to reach a disease remission state as early as possible and maintain long-term stability. Clinically, the common therapeutic drugs for RA fall into three major categories: non-steroidal anti-inflammatory drugs (NSAIDS), Glucocorticoids (GCS) and disease modifying antirheumatic drugs (DMARDS). Methotrexate (MTX) is the first choice for antirheumatic drugs (DMARDS),
but can bring systemic symptoms such as hypodynamia, fever and the like, digestive tract symptoms such as upper abdominal discomfort, inappetence, oral ulceration, digestive tract hemorrhage and the like, and adverse reactions such as blood cell three-system reduction and the like. The medicines are difficult to popularize or use for a long time due to unfavorable curative effects or large toxic and side effects. RA belongs to the category of arthralgia syndrome in traditional Chinese medicine, and astragalus-cassia twig five-material decoction (astragalus, cassia twig, peony, ginger and Chinese date) or cassia twig-peony-rhizoma anemarrhenae decoction (cassia twig, peony, liquorice, ephedra, ginger, bighead atractylodes rhizome, rhizoma anemarrhenae, radix sileris and prepared monkshood) is a relatively famous compound and has small side effect, but the treatment effect is not very ideal.
Disclosure of Invention
The invention aims to solve the technical problems in the prior art and provides a traditional Chinese medicine preparation for treating rheumatoid arthritis, which has small side effect and good curative effect.
The technical solution of the invention is as follows: the traditional Chinese medicine preparation for treating rheumatoid arthritis is characterized by being an oral traditional Chinese medicine water extract, and the traditional Chinese medicines comprise the following components in percentage by mass: 35 parts of astragalus membranaceus, 15 parts of cassia twig, 25 parts of fried white peony root, 10 parts of fried monkshood, 15 parts of angelica, 25 parts of coix seed, 15 parts of divaricate saposhnikovia root, 15 parts of large-leaved gentian, 10 parts of notopterygium root, 10 parts of ligusticum wallichii, 15 parts of rhizoma atractylodis and 15 parts of liquorice.
The traditional Chinese medicine used in the invention has small toxic and side effects, and the results of the detection of the joint swelling degree of the treated mice and the contents of RF, TNF alpha, IL-6 and IL-10 in serum show that the curative effect of the traditional Chinese medicine on rheumatoid arthritis is superior to that of the prior art.
Detailed Description
The traditional Chinese medicine preparation for treating rheumatoid arthritis is an oral traditional Chinese medicine water extract, and the traditional Chinese medicines comprise the following components in parts by mass: 35g of astragalus, 15g of cassia twig, 25g of fried white peony root, 10g of fried monkshood, 15g of angelica, 25g of coix seed, 15g of divaricate saposhnikovia root, 15g of large-leaved gentian, 10g of notopterygium root, 10g of szechuan lovage rhizome, 15g of rhizoma atractylodis and 15g of liquorice.
The preparation method comprises decocting radix Aconiti lateralis Preparata in water for 30min, soaking the rest Chinese medicinal materials in 10 times of double distilled water for 30min, adding into radix Aconiti lateralis Preparata water decoction, boiling with strong fire, decocting with slow fire for 2 hr, cooling, and adding into container. Adding 8 times of double-distilled water into the residue, boiling with strong fire, adjusting to slow fire, decocting for 2 hr, pouring the medicinal liquid into a container, and mixing the two medicinal liquids. Then, the medicinal liquid in the container is concentrated on a rotary evaporator to prepare an extracting solution with the specific gravity of 4 g/mL.
Experiment:
1. grouping
80 SD rats with the dose of 200 +/-20 g are fed adaptively for 1 week, and are randomly divided into 8 groups, 10 blank groups, 10 model groups, 10 positive groups, 10 low-dose groups in the embodiment of the invention, 10 doses in the embodiment of the invention, 10 high-dose groups in the embodiment of the invention, 10 astragalus mongholicus and cassia twig five-ingredient decoction groups and 10 cassia twig, peony and rhizoma anemarrhenae decoction groups.
Preparation of rat rheumatoid arthritis model
Referring to the Freund modeling method, SD rats are fully anesthetized in abdominal cavity by 10% chloral hydrate (0.3 mL/100 g) (no blinking reaction and no pain when pinching feet), the right toes are sterilized by 75% alcohol, except for the blank rats, the rats in the other groups are injected with 0.2mL of complete Freund's adjuvant at multiple points under the skin, the rats are injected with 0.1mL of complete Freund's adjuvant once after 1 week to enhance immunity, and the rats are subjected to arthritis scoring for 4 minutes after half a month; the rats in the blank group were injected with an equal amount of physiological saline.
3. Pharmaceutical preparation
Astragalus and cassia twig five-herb decoction: is prepared from astragalus root (15 g), cinnamon twig (12 g), peony root (12 g), ginger (25 g) and jujube (4). The extraction process is the same as that of the embodiment of the invention, and 4g/mL of extract is prepared.
Cassia twig, peony and rhizoma anemarrhenae decoction: is proportionally prepared from cassia twig (12 g), peony (9 g), liquorice (6 g), ephedra (12 g), ginger (15 g), white atractylodes rhizome (15 g), anemarrhena rhizome (12 g), ledebouriella root (12 g) and prepared aconite root (10 g). The extraction process is the same as that of the embodiment of the invention, and 4g/mL of extract is prepared.
4. Administration of drugs
Normal group and model group were administered with a therapeutic dose of physiological saline 24 hours after molding; the positive medicine methotrexate is prepared by normal saline and dissolved by ultrasound, the administration concentration is 0.1 mg/mL, and the administration dose is 1 mg/kg; the low, medium and high dose groups of the embodiment of the invention are administrated to the embodiment of the invention, and the administration dose is 10 g/kg, 20 g/kg and 40g/kg respectively; the administration dosage of the astragalus mongholicus and cassia twig five-component decoction group is 40 g/kg; the administration dosage of the cassia twig, peony and rhizoma anemarrhenae decoction group is 40 g/kg. Each group was administered once daily for 5 weeks.
5. Detection of
And measuring the swelling degree of the joint by using a vernier caliper every week after the molding, and calculating and recording the increase percentage of the swelling degree of the joint. The calculation formula is% increase in joint swelling degree = (joint diameter-initial diameter at the measured time point)/initial diameter × 100%. After the last administration, rat serum is taken, the enzyme linked immunosorbent assay is used for detecting the contents of RF, TNF alpha, IL-6, IL-10 and IL-1 beta in the serum, and the specific detection steps and the method are operated according to the kit instruction.
6. Statistical method
All data are calculated by SPSS16.0 software, and the average value plus or minus standard deviation is used for measuring data
Figure 96763DEST_PATH_IMAGE001
Representing, inter-group comparison Using independent samplestAnd (4) checking the test result,pless than or equal to 0.05 has statistical significance.
7. Results
7.1 results of joint swelling degree are shown in tables 1-1 and 1-2.
TABLE 1-1
Figure 591329DEST_PATH_IMAGE002
Tables 1 to 2
Figure 701106DEST_PATH_IMAGE003
*P<0.05, **P<0.01, compared to a model set;#P<0.05, ##P<0.01, compared to the blank group.
The results show that: at each time point, the blank control group and the model group have significant difference, which indicates that the molding is successful. From the third week, the positive drug group and the model group have significant difference, which indicates that methotrexate has therapeutic effect. From the fourth week, the administration groups and the model groups of the embodiments of the invention have significant differences, which shows that the embodiments of the invention have the treatment effect on rheumatoid diseases. From the fourth week, the ratio of the astragalus-cassia twig five-ingredient decoction group and the cassia twig-peony-rhizoma anemarrhenae decoction group to the model group has statistical significance, which shows that the astragalus-cassia twig five-ingredient decoction and the cassia twig-peony-rhizoma anemarrhenae decoction have treatment effect on rheumatoid arthritis, and meanwhile, the curative effect of the embodiment of the invention is better than that of the positive medicine group, the astragalus-cassia twig five-ingredient decoction group and the cassia twig-peony-rhizoma anemarrhenae decoction group.
7.2 serum RF, TNF alpha, IL-6, IL-10 content detection results are shown in tables 2-1, 2-2
TABLE 2-1
Figure 306530DEST_PATH_IMAGE004
Tables 2 to 2
Figure 178672DEST_PATH_IMAGE005
*P<0.05, **P<0.01, compared to a model set;#P<0.05, ##P<0.01, compared to the blank group.
The results show that:
RF: the blank group and the model group have statistical significance, and the success of the model building is prompted; the ratio of the positive medicine group to the model group to the blank group has statistical significance, so that the RF is close to the normal level, and the methotrexate is prompted to have a therapeutic effect. The low dose group of the embodiment of the invention has statistical significance compared with the model group and the positive drug group, and the low dose group of the embodiment of the invention has the function of relieving rheumatoid arthritis. Compared with the positive medicine group, the dose group and the model group in the embodiment of the invention have statistical significance and have no statistical significance, and the fact that the dose in the embodiment of the invention has a treatment effect on rheumatoid arthritis is prompted. The high-dose group, the model group and the positive medicine group in the embodiment of the invention have statistical significance, and the RF is closer to the normal level, which prompts that the high-dose treatment effect of the embodiment of the invention is better than that of methotrexate. The ratio of the astragalus mongholicus-cassia twig five-ingredient decoction group to the cassia twig-peony-rhizoma anemarrhenae decoction group to the model group has statistical significance, and the astragalus mongholicus-cassia twig five-ingredient decoction and the cassia twig-peony-rhizoma anemarrhenae decoction are prompted to have a treatment effect on rheumatoid arthritis, but the treatment effect is only superior to that of the low-dose group in the embodiment of the invention and is not superior to that of the high-dose group in the embodiment of the invention.
② TNF α: the blank group and the model group have statistical significance, and the success of the model building is prompted; compared with a blank group, the positive medicine group and the model group have statistical significance, and have no statistical significance, so that the methotrexate has an excellent treatment effect. The low dose group of the embodiment of the invention has statistical significance compared with the model group and the positive drug group, and the low dose group of the embodiment of the invention has the function of relieving rheumatoid arthritis. The dose group, the model group and the positive medicine group in the embodiment of the invention have statistical significance, and the fact that the dose in the embodiment of the invention has a treatment effect on rheumatoid arthritis is prompted. The high-dose group, the model group and the positive drug group in the embodiment of the invention have statistical significance, and the TNF alpha is close to the normal level, which prompts that the high-dose group in the embodiment of the invention has treatment effect. The ratio of the astragalus mongholicus-cassia twig five-ingredient decoction group to the cassia twig-peony-rhizoma anemarrhenae decoction group to the model group has statistical significance, which suggests that the astragalus mongholicus-cassia twig five-ingredient decoction and the cassia twig-peony-rhizoma anemarrhenae decoction have a treatment effect on rheumatoid arthritis, but the treatment effect is equivalent to that of the low-dose group and the medium-dose group in the embodiment of the invention, and the effect is inferior to that of the high-dose group in the embodiment of the invention.
③ IL-6: the blank group and the model group have statistical significance, and the success of the model building is prompted; the ratio of the positive medicine group to the model group to the blank group has statistical significance, so that the IL-6 is close to the normal level, and the methotrexate is prompted to have a therapeutic effect. The low dose group and the model group in the embodiment of the invention have no statistical significance, which indicates that the low dose in the embodiment of the invention has no treatment effect. The ratio of the dose group to the model group and the positive drug group in the embodiment of the invention has statistical significance, and the suggestion is that the dose in the embodiment of the invention has a treatment effect on rheumatoid arthritis, but the treatment effect is not obvious. The high-dose group and the model group in the embodiment of the invention have statistical significance, and have no statistical significance with the positive medicine group, so that IL-6 is close to a normal level, and the effect of treating rheumatoid arthritis by the high-dose group in the embodiment of the invention is prompted. The ratio of the astragalus mongholicus-cassia twig five-ingredient decoction group to the cassia twig-peony-rhizoma anemarrhenae decoction group to the model group has statistical significance, and the astragalus mongholicus-cassia twig five-ingredient decoction and the cassia twig-peony-rhizoma anemarrhenae decoction are prompted to have a treatment effect on rheumatoid arthritis, but the treatment effect is equivalent to that of the dose group in the embodiment of the invention, and is not the same as that of the high dose group in the embodiment of the invention.
IL-10: the blank group and the model group have statistical significance, and the success of the model building is prompted; the ratio of the positive medicine group to the model group to the blank group has statistical significance, so that the IL-10 is close to the normal level, and the methotrexate is prompted to have a therapeutic effect. The low dose group and the model group in the embodiment of the invention have statistical significance, and the low dose group in the embodiment of the invention is not effective to rheumatoid arthritis. The ratio of the dose group to the model group and the positive drug group in the embodiment of the invention has statistical significance, and the suggestion is that the dose in the embodiment of the invention has a treatment effect on rheumatoid arthritis, but the treatment effect is not obvious. The high-dose group of the embodiment of the invention has statistical significance compared with the model group and the positive medicine group, and the high-dose group of the embodiment of the invention has a treatment effect on rheumatoid arthritis. The ratio of the astragalus mongholicus-cassia twig five-ingredient decoction group to the cassia twig-peony-rhizoma anemarrhenae decoction group to the model group has statistical significance, and the astragalus mongholicus-cassia twig five-ingredient decoction and the cassia twig-peony-rhizoma anemarrhenae decoction are prompted to have a treatment effect on rheumatoid arthritis, but the treatment effect is equivalent to that of the dose group in the embodiment of the invention, and is not the same as that of the high dose group in the embodiment of the invention.

Claims (1)

1. The traditional Chinese medicine preparation for treating rheumatoid arthritis is characterized by being an oral traditional Chinese medicine water extract, and the traditional Chinese medicines comprise the following components in percentage by mass: 35 parts of astragalus membranaceus, 15 parts of cassia twig, 25 parts of fried white peony root, 10 parts of fried monkshood, 15 parts of angelica, 25 parts of coix seed, 15 parts of divaricate saposhnikovia root, 15 parts of large-leaved gentian, 10 parts of notopterygium root, 10 parts of ligusticum wallichii, 15 parts of rhizoma atractylodis and 15 parts of liquorice.
CN201810865992.2A 2018-08-01 2018-08-01 Traditional Chinese medicine preparation for treating rheumatoid arthritis Active CN108578606B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810865992.2A CN108578606B (en) 2018-08-01 2018-08-01 Traditional Chinese medicine preparation for treating rheumatoid arthritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810865992.2A CN108578606B (en) 2018-08-01 2018-08-01 Traditional Chinese medicine preparation for treating rheumatoid arthritis

Publications (2)

Publication Number Publication Date
CN108578606A CN108578606A (en) 2018-09-28
CN108578606B true CN108578606B (en) 2021-02-19

Family

ID=63619053

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810865992.2A Active CN108578606B (en) 2018-08-01 2018-08-01 Traditional Chinese medicine preparation for treating rheumatoid arthritis

Country Status (1)

Country Link
CN (1) CN108578606B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113134064A (en) * 2021-04-27 2021-07-20 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Composition for preventing rheumatoid arthritis and preparation method and application thereof
CN115814048A (en) * 2022-12-09 2023-03-21 北京马家一绝中医风湿骨病研究院 Chinese medicine for treating rheumatism and its preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"薏苡仁汤结合针灸治疗寒湿闭阻型类风湿性膝关节炎45例";崔丽娜;《黑龙江中医药》;20121231(第5期);第38-39页 *
"论治‘痹证’300例分析";张维杰;《甘肃中医》;19931231;第6卷(第5期);第19-20页 *

Also Published As

Publication number Publication date
CN108578606A (en) 2018-09-28

Similar Documents

Publication Publication Date Title
US10813964B2 (en) Shenlingbaizhu granules and preparation method thereof
WO2014094632A1 (en) Pharmaceutical composition for treating headache, and preparation method thereof
CN108578606B (en) Traditional Chinese medicine preparation for treating rheumatoid arthritis
CN115400194A (en) Traditional Chinese medicine composition for treating childhood epidemic and application thereof
CN103285230B (en) Pharmaceutical composition for treating pharyngitis and preparation method thereof
CN111375035B (en) Preparation and application of enteric-coated preparation for treating cervical spondylosis
WO2023197731A1 (en) Traditional chinese medicine composition, preparation method therefor and use thereof
CN113730464A (en) New application of rhizoma coptidis pill, extract and pharmaceutical composition thereof and rhizoma coptidis pill product
CN114848703B (en) Tibetan medicine formula with rheumatoid arthritis treatment effect, preparation method and application thereof
CN107468955B (en) Traditional Chinese medicine for treating gouty arthritis and preparation method
CN105168284A (en) Application of panax japonicus saponins V and total panax japonicus saponins thereof to preparation of medicament for resisting urathritis
CN101978982A (en) Application of Japanese ginseng or extract thereof to preparation of medicament for resisting gout and repairing hyperuricemic kidney injury
CN104324316A (en) Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer
CN116251150A (en) Traditional Chinese medicine composition and application thereof
CN101590208B (en) Medicament composition for treating rheumatoid arthritis, and preparation method thereof
CN112274613A (en) Pharmaceutical composition for treating knee osteoarthritis
CN108888731B (en) Pharmaceutical composition for relieving cough and reducing sputum
CN111494446B (en) Traditional Chinese medicine composition for treating biliary colic and application thereof
CN116159098B (en) Composition for preventing and treating degenerative osteoarthritis lesions
CN1899436A (en) Method for preparing Chinese medicine compound preparation and use
CN106728836B (en) Traditional Chinese medicine composition for treating infantile viral myocarditis and preparation method thereof
CN115444887A (en) Traditional Chinese medicine composition for treating ischemic cerebral apoplexy and preparation method thereof
CN117731680A (en) Pharmaceutical composition for treating infantile diarrhea, and preparation method and application thereof
CN117045756A (en) Traditional Chinese medicine composition and medical application thereof
CN117731619A (en) Preparation method of pharmaceutical composition for activating blood circulation to dissipate blood stasis and relieving pain

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant